Choosing an SCIg Infusion vs IVIg Infusion

SCIg vs IVIg: Differences between routes of administration

Who Infusion usually performed by an HCP Infusion can be performed by patients or caregivers after training
Where Is usually performed in a healthcare facility Once trained, treament almost anywhere (home, office, travel)

Studies have demonstrated that SCIg delivery is feasible, safe, efficient and cost-effective1-4

SCIg infusions have steadily replaced IVIg infusions1

Many patients prefer SCIg for multiple reasons:1-4

Icon of a houseHome

Icon of a schoolSchool

Icon of person working at deskOffice/Work

Icon of suitcaseTravel

  • Ability to self-administer or administration by the patients’ caregiver after training almost anywhere: home, school, office, work, travel, etc.
  • Allows greater freedom and convenience
  • Minimal impact on family, work, and school activities
  • Removes the need to travel to infusion clinics or hospital

Cutaquig allows patients to comfortably switch from IVIg to SCIg, enabling the transition to home care.5

IVIg vs SCIg Infusion: Concentrations over time

SCIg treatment provides stable serum immunoglobulin levels6

  • Traditionally, maintenance replacement SCIg therapy is preceded by a switch from existing IVIg therapy
  • In most cases, the first SCIg infusion is given 1 week after the last IVIg infusion in order to maintain high serum immunoglobulin levels
  • Thereafter, the average daily immunoglobulin level achieved with IVIg can be maintained with regular subcutaneous infusions

Serum immunoglobulin levels achieved with IVIg and/or SCIg administration6

Serum IgG Concentration Graph

Jolles S, Stein MR, Longhurst HJ et al. Biol Therapy. 2011; 1: 3.

Learn more about the ease of administration and pharmacokinetics of cutaquig.

Learn more

  1. Kobayashi RH, Gupta S, Melamed I, et al. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (octanorm [cutaquig®]) in the Treatment of Patients with Primary Immunodeficiencies. Front Immunol. February 2019 | Volume 10 | Article 40.
  2. McCormack PL. Immune Globulin Subcutaneous (Human) 20% In Primary Immunodeficiency Disorders. Drugs. 2012; 72 (8): 1087-1097.
  3. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics: Targets and Therapy.2012:6 277–287.
  4. Berman K. Safety, Efficacy, Tolerability, Advantages and Disadvantages of Intravenous and Subcutaneous Immune Globulin Therapy. Highlights from IG Living Teleconference December 10, 2015.
  5. Data on file, Octaphama.
  6. Jolles S, Stein MR, Longhurst HJ et al. New Frontiers in Subcutaneous Immunoglobulin Treatment. Biol Therapy. 2011; 1: 3.